For Immediate Release
Chicago, IL – December 15, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corporation (NASDAQ:NVDA) NVDA, Philip Morris International Inc (NYSE:PM). PM, Sanofi (NASDAQ:SNY) SNY, Applied Materials (NASDAQ:AMAT), Inc. AMAT and The Goldman Sachs Group (NYSE:GS), Inc. GS.
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for NVIDIA, Philip Morris and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA, Philip Morris and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of NVIDIA have outperformed the Zacks General Semiconductor industry over the past year (+111% vs. +58.5%). The Zacks analyst believes that NVIDIA has been benefiting from the work and learn-from-home wave due to the ongoing pandemic.
NVDA is also benefiting from strong growth in GeForce desktop and notebook Graphic Processing Units, which is boosting gaming revenues. A surge in Hyperscale demand remains a tailwind for its Data Center business. Expansion of NVIDIA GeForce NOW is expected to drive the user base. NVIDIA’s management, however, expects the pandemic to impact near-term revenues.
(You can read the full research report on NVIDIA here >>>)
Philip Morris shares have gained +15% in the year to date period against the Zacks Tobacco industry’s gain of +12.3%. The Zacks analyst believes that Philip Morris has been benefiting from its pricing power, which also aided its third-quarter 2021 results. PM gained from higher pricing across most regions.
Strength in the reduced-risk products (or RRPs) category is another major positive for Philip Morris. The popularity of IQOS has also been a strong driver of growth for PM despite its short supply concerns. The global semiconductor shortage, however, remains a major headwind for Philip Morris. PM expects limited recovery in its duty-free business in the fourth quarter, as intercontinental travel remains subdued.
(You can read the full research report on Philip Morris here >>>)
Shares of Sanofi have lost -9.5% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +8.2%, although things seem to be improving. The Zacks analyst believes that Dupixent has become the key top-line driver for Sanofi due to its regular label expansion.
With revenues from outside of the U.S. accelerating, and multiple approvals for new indications expected in the near future, Dupixent’s sales are expected to rise. Sanofi possesses a leading vaccine operation, which contributes significantly to its top-line. Generic competition for several of its products, however, remains a key headwind for Sanofi.
(You can read the full research report on Sanofi here >>>)
Other noteworthy reports we are featuring today include Applied Materials and Goldman Sachs.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report
Sanofi (SNY): Free Stock Analysis Report
Philip Morris International Inc. (PM): Free Stock Analysis Report
NVIDIA Corporation (NVDA): Free Stock Analysis Report
Applied Materials, Inc. (AMAT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research